BioSpace News Archive

ICE3 is the largest controlled, multicenter clinical trial ever performed in the U.S. for liquid nitrogen-based cryoablation of small, low-risk, early-stage malignant breast tumors.

Avenge Bio, Inc. today announced that three abstracts were selected for presentation as posters at the Society of Immunotherapy of Cancer.

Ferring Pharmaceuticals today announced that it will presenting a company-sponsored abstract highlighting an in-depth analysis of future trends in the Assisted Reproductive Technology (ART) market and will also host a product theater at the American Society for Reproductive Medicine (ASRM) 2022 Scientific Congress & Expo taking place October 22-26 in Anaheim, CA.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at 2:30 p.m. Pacific time (5:30 p.m. Eastern time).

Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of a new digital donor experience to enhance access to its donor centers in four distinct US geographic markets.

Longhorn Vaccines and Diagnostics LLC today announced that it will present two abstracts at Infectious Disease (ID) Week, being in Washington, DC, Oct. 19 – 23, 2022.

A new study delivers promising findings for parents and caregivers seeking a natural alternative to manage pediatric Attention-Deficit Hyperactivity Disorder (ADHD) behavior.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that Daniela Santiesteban, Ph.D., Salarius’ director of targeted protein degradation development, will be presenting at the 5th Annual Targeted Protein Degradation Conference being held October 25-28 in Boston.

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced the results of pan-cancer early detection test SeekInCare® were presented at The 2022 Early Detection of Cancer Conference in Portland, Oregon.

NanoVibronix, Inc today announced that on October 17, 2022, a Nasdaq Hearings Panel (the “Panel”) granted the Company’s request for continued listing on The Nasdaq Capital Market.